Compare NCMI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | PRME |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 536.4M |
| IPO Year | 2006 | 2022 |
| Metric | NCMI | PRME |
|---|---|---|
| Price | $3.06 | $2.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.63 | ★ $7.56 |
| AVG Volume (30 Days) | 267.3K | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 52.17 | 18.18 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $11.20 | $7.06 |
| Revenue Next Year | $6.22 | $47.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $2.80 | $1.18 |
| 52 Week High | $5.56 | $6.94 |
| Indicator | NCMI | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 38.65 |
| Support Level | $2.86 | N/A |
| Resistance Level | $3.76 | $3.97 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 26.98 | 28.96 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.